# A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

> **NCT06993792** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 1200 (estimated)

## Conditions studied

- Obesity
- Overweight
- Type 2 Diabetes

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06993792
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06993792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06993792, "A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06993792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*